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SUMMARY
The aim of this review was to understand the landscape of serum
ferritin in diagnosing iron deficiency in the aetiology of anaemia
in pregnancy. Iron deficiency in pregnancy is a major public
health problem leading to the development of anaemia. Reduc-
ing the global prevalence of anaemia in women of reproduc-
tive age is a 2025 global nutrition target. Bone marrow aspira-
tion is the gold standard test for iron deficiency but requires an
invasive procedure; therefore, serum ferritin is the most clin-
ically useful test. We undertook a systematic search of elec-
tronic databases and trial registers from inception to January
2016. Studies of iron or micronutrient supplementation in preg-
nancy with pre-defined serum ferritin thresholds were included.
Two independent reviewers selected studies, extracted data and
assessed quality. There were 76 relevant studies mainly of obser-
vational study design (57%). The most commonly used thresh-
olds of serum ferritin for the diagnosis of iron deficiency were
<12 and <15 ng mL−1 (68%). Most primary studies provided no
justification for the choice of serum ferritin threshold used, but
25 studies (33%) used thresholds defined by expert consensus in
a guideline development process. There were five studies (7%)
using a serum ferritin threshold defining iron deficiency derived
from primary studies of bone marrow aspiration. Unified inter-
national thresholds of iron deficiency for women throughout
pregnancy are required for accurate assessments of the global
disease burden and for evaluating effectiveness of interventions
addressing this problem.
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What is known about the topic?
• There is variation in serum ferritin thresholds used to
define iron deficiency in pregnancy, a condition with
a large global burden of disease.
What is new?
• This variation leads to challenges in interpreting
results of clinical interventions managing iron
deficiency in pregnancy.
What are the future key questions for work on the
topic?
• Accurate and internationally unified definitions of
iron deficiency using serum ferritin in pregnancy are
required.
Iron deficiency is the most common micronutrient defi-
ciency in the world and the most common cause of anaemia
(Kassebaum, 2016). A 50% reduction of anaemia in women of
reproductive age by the year 2025 is a global nutrition target
(World Health Organization, 2014). Iron deficiency anaemia
(IDA) was also the most common cause of anaemia-related
disability in 2013 (Kassebaum, 2016). IDA affects one in four
pregnancies in Europe (McLean et al., 2009; Scholl, 2010). Glob-
ally, the prevalence of anaemia in pregnant women in 2011 was
estimated to be 38%, equivalent to 32 million women (Stevens
et al., 2013). Prevalence of iron deficiency in the absence of
anaemia is estimated to be between 30 and 60% (Daru et al.,
2016). As erythropoiesis becomes more and more compromised,
iron stores progress from being replete to reduced and finally
depleted, resulting in anaemia (Scholl, 2005; Pavord et al., 2012).
Both anaemic and non-anaemic iron deficiencies in pregnancy
have consequences for both the mother and their offspring
(Scholl, 2011; Acosta et al., 2014). There are data demonstrating
long-term impairments in cognitive development and growth
in babies exposed to IDA in utero (Congdon et al., 2012).
Therefore, prevention and treatment of anaemia and iron
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deficiency is a priority to clinicians and policy makers in all
countries (World Health Organization, 2011).
The traditional gold standard for defining iron deficiency
is based on the absence of staining for haemosiderin on bone
marrow aspirate viewed under microscopy, demonstrating a
lack of iron available for erythropoiesis (Gale et al., 1963). This
requires an invasive procedure not suitable for routine use.
There are multiple biomarkers available for determining iron
status by sampling peripheral blood. Of these, serum ferritin is
the most clinically applicable in pregnancy (Pavord et al., 2012).
There is variation in serum ferritin thresholds used to define
iron deficiency in primary studies and in different policy docu-
ments (MMWR, 1998; World Health Organization, 2001). This
makes it difficult to understand the scale of iron deficiency and
interpret the effectiveness of interventions both at individual
and population levels (Garcia-Casal et al., 2014).
This systematic review was prospectively designed to inves-
tigate the range and characteristics of the thresholds of serum
ferritin used to diagnose iron deficiency in pregnant women,
used in primary intervention studies and national and interna-
tional guidelines.
MATERIALS AND METHODS
This review was designed to describe the current landscape of
serum ferritin use in defining iron deficiency in pregnancy. It was
prospectively registered (PROSPERO CRD42016037414) and
was conducted and reported in compliance with the Preferred
Reporting Items for Systematic Reviews (PRISMA) guidelines
(Moher et al., 2009).
Data sources and study selection
A database search, without language restrictions, was performed
from conception to January 2016 on EMBASE, MEDLINE, The
Cochrane Library, CINAHL, AMED and SIGLE. Searches of the
following regional and international databases were also con-
ducted in August 2015: CENTRAL, Web of Science, POPLINE,
Open Grey, DARE, IBECS (http://ibecs.isciii.es/), Scielo (http://
www.scielo.br/), WHO Global Index Medicus (GIM): African
Index and Medicus (AIM), Index Medicus for the WHO East-
ern, Mediterranean Region (IMEMR), LILACS, Pan Ameri-
can Health Library (PAHO), Western Pacific Region Index
Medicus (WPRIM), Index Medicus for South-East Asia Region
(IMSEAR) and the WHO Library (WHOLIS). Searches aimed to
identify all studies of iron or multiple micronutrient supplemen-
tation of any study design without language or date restrictions.
The following subject headings and the key words, including
‘ferritin’, ‘ferritins’, ‘serum’, ‘plasma’, ‘diagnosis’ and ‘diagnostic’,
were used (Appendix S1, Supporting Information).
Studies were selected using a two-stage process. First, two
independent reviewers (J. D. and J. A.) screened the titles and
abstracts to identify eligible studies; this was followed by retrieval
and assessment of the full-text manuscripts of relevant citations.
Any disagreements were resolved after discussion with a third
reviewer (K. S. K.). We included studies with any design, con-
ducted on pregnant or post-partum women, carrying single-
ton or multiple pregnancies, where pre-defined thresholds of
serum ferritin for iron deficiency were used. We included studies
with any laboratory ferritin assay used. Studies were excluded if
authors had not pre-specified values for iron deficiency accord-
ing to serum ferritin concentrations prior to administering an
intervention but had selected a value based on response to treat-
ment. A 𝜅 coefficient of inter-rater reliability was calculated
(Landis and Koch, 1977).
Data extraction and analysis
Data from selected studies were independently extracted by two
reviewers (J. D. and J. A.) using a piloted data extraction form.
Data were collected on the rationale for the threshold-defining
iron deficiency used, study design, geographical location of
the studies and whether these study locations were in areas
where soil-transmitted helminthiasis or malaria infections were
endemic. Because of the nature of this review, data are pre-
sented and analysed descriptively as meta-analysis was not pos-
sible (Higgins, 2012). The results were tabulated, and all serum
ferritin thresholds were converted to nanogram per millilitre to
allow ease of comparison.
Quality assessment
We used first principles to develop a strategy to objectively
assess the quality of primary studies included in this review. The
quality assessment tool contained six prompt questions. These
were developed in collaboration with four experienced review-
ers, international policy makers and clinicians from varied back-
grounds. Two iterations of these prompt questions were required
before the tool was finalised. The tool was piloted before being
implemented in this review. The prompt questions and scoring
system are outlined below. A score of 3 or more points was con-
sidered high quality. The maximum possible score achievable
was 5, with a minimum score of 1 based on our inclusion and
exclusion criteria.
1. Did the authors use a pre-specified (a priori) threshold for
serum ferritin in the study? (1 point).
2. Was a published reference for the pre-specified threshold
provided? (1 point).
3. Was the threshold derived from a comparison with the
existing gold standard test (bone marrow aspirate) (1
point).
4. If not derived from a comparison with an existing gold
standard test, was the threshold defined by a consensus of
experts for any of the following (Jones and Hunter, 1995):
a. From a guideline development process (Rycroft-
Malone, 2001) (1 point)
b. Based on patient-reported outcomes (Man-Son-Hing
et al., 2000) (1/2 point)
Transfusion Medicine, 2017 © 2017 World Health Organization licensed by
Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society.
Serum ferritin for defining iron deficiency in pregnancy 3
c. Based on statistical analysis of existing data (Rycroft-
Malone, 2001) (1/2 point)
5. Does the selected threshold correlate to improved clinical
outcomes (Grimshaw and Russell, 1993) (1 point).
6. Did the authors consider factors other than the disease
of interest that may influence measurement of serum fer-
ritin (e.g. multiple pregnancies, malaria, soil-transmitted




There were 9612 citations identified following the two electronic
searches. Of these, 1256 citations were pregnancy-specific. After
screening titles and abstracts, 126 citations were eligible for
full-text review. Finally, 76 studies were included in the system-
atic review (Fig. 1). The 𝜅 statistic was 0·88, demonstrating excel-
lent agreement between reviewers (Higgins, 2012).
Study characteristics
Of the 76 included studies, 29 (38%) were conducted in women
carrying singleton pregnancies (Table S1); the remaining were
carried out in a mixed population of singleton and multiple
pregnancies. A total of 24 (32%) were conducted in countries
where parasitic infections, including malaria and/or hookworm
infection, were endemic.
The studies included in the review were of varying method-
ological quality (Fig. 2). Of the included studies, 47% (36 studies)
were of good quality, scoring 3 or more points on the quality
assessment tool. All of the studies included in the review pro-
vided an a priori threshold of serum ferritin-defining iron defi-
ciency. Only 47% (36 studies) provided a reference to the source
from which the threshold was derived (Fig. 2). There were five
studies (7%) where the choice of serum ferritin threshold was
based on a published primary study comparing serum ferritin
measurements with bone marrow aspirates (Fig. 2). There were
28 studies (37%) where consensus methods were used to deter-
mine the threshold of serum ferritin used in the intervention
study. Of these, 25 (33%) utilised consensus methods used in
guideline development processes, one using consensus methods
to develop patient-reported outcomes and two using statistical
analysis of existing data sets. There were six studies (8%) that
used improvements in clinical outcomes (such as improvements
in anthropometric measurements and nutritional status, neona-
tal birth weight and gestational age at delivery and iron endow-
ment as measured by cord ferritin) following an intervention
to identify the threshold of serum ferritin used to best define
iron deficiency. There were 31 studies (41%) that considered
the impact of external factors on the threshold used to define
iron deficiency. This included factors such as multiple pregnancy
and/or parasitic infections, including malaria (known to cause
an acute phase reaction and rise in serum ferritin) or hookworm
Full-text articles 
excluded, (n=50) 
Unable to acquire 
full text: 10  
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(n = 9,612) 
Fig. 1. Flow chart of studies included in this systematic review of serum
ferritin thresholds defining iron deficiency in pregnancy.
infestation (known to cause intestinal disease, increasing blood
losses).
Study methodology
The largest number of individual studies of iron interventions
were conducted in India (15 in total), followed by China (5 in
total) (Fig. 3). There were several areas of sub-Saharan Africa
where no studies meeting the review criteria were found, similar
to parts of Eastern Europe, Russia and South America. The most
frequently used study design was longitudinal, including longi-
tudinal cohort design (Fig. 4). The most commonly used thresh-
olds of serum ferritin to diagnose iron deficiency in studies of
iron and/or micronutrient supplementation in pregnant women
were serum ferritin levels <12 (35 studies) and <15 ng mL−1 (17
studies). Other commonly used thresholds defining iron defi-
ciency in pregnancy included serum ferritin <20 (8 studies) and
<30 ng mL−1 (6 studies). Other serum ferritin thresholds (<6,
<10, <50, and <60 ng mL−1) were used less commonly.
There were 40 studies that did not provide any justification or
reference for the choice of serum ferritin threshold used (Fig. 2).
Of the remaining studies that did, 10 studies cited the World
Health Organization (WHO) 2001 guidelines as the reference
for the threshold used; 9 studies referenced the Centres for Dis-
ease Control and Prevention (CDC) 1998 guidelines (MMWR,
1998) as the reference for the threshold used; 8 of the included
studies referenced primary studies, including comparing serum
ferritin levels with bone marrow aspirates taken from pregnant
populations; and/or studies deriving thresholds from statistical
analyses of laboratory reference ranges. The remaining studies
included in this review referred to national guidelines and other
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Study quality assessment 
Fig. 2. Quality assessment of studies included in the review of serum ferritin thresholds defining iron deficiency in pregnancy. Based on a quality






Key (thresholds, ng ml-1) 
Fig. 3. World map demonstrating the geographical distribution of serum ferritin thresholds used in studies of iron or multiple micronutrient
supplementation in pregnancy. Shaded areas demonstrate countries contributing data to this systematic review.
published literature reviews as references for the thresholds
defining iron deficiency used.
DISCUSSION
Main findings
This systematic review demonstrates the variation in the serum
ferritin thresholds used to diagnose iron deficiency in pregnancy
in research settings in the published literature. This variation
was seen across a variety of study designs assessing the effects
of iron interventions in different populations and geographical
areas. Owing to the paucity of published data, a review of the
diagnostic accuracy of serum ferritin thresholds defining iron
deficiency in pregnancy is not possible. The data in this review
demonstrate that a consensus on a particular threshold of serum
ferritin for defining iron deficiency is lacking. The variation
in thresholds leads to uncertainty regarding the diagnosis and
optimal treatment of iron deficiency in pregnancy, with resultant
consequences for both the mother and the offspring.
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Threshold of serum ferritin (ng ml–1) 
Fig. 4. Histogram of serum ferritin (ng mL−1) thresholds defining iron deficiency in pregnancy, arranged by study design.
*A threshold of <12 ng mL−1 for antenatal women and <15 ng mL−1 for post-natal women was used in this study.
Iron deficiency and IDA increases the maternal risk of mortal-
ity secondary to haemorrhage (Cantwell et al., 2011) and sepsis
(Bamber and Kinsella, 2015) with significant cost implications
(Goonewardene et al., 2012). Severe maternal sepsis is the lead-
ing cause of maternal death in the UK, affecting 4·7 per 10 000
pregnancies (Acosta et al., 2014; Bamber and Kinsella, 2015). If
anaemic women become septic, the risk of mortality is doubled
(Acosta et al., 2014). Chronic fetal exposure to iron deficiency
leads to low birth weight (Lone et al., 2004) and doubles the
risk of pre-term delivery (Beck et al., 2010). Moreover, there are
emerging empirical data demonstrating that iron supplementa-
tion when iron stores are not depleted may also be associated
with adverse maternal and fetal outcomes (Congdon et al., 2012;
Siu, 2015), further highlighting the need for an accurate and uni-
fied threshold.
The adverse outcomes related to IDA are preventable by accu-
rate diagnosis and timely treatment. The findings of this review
show that the most frequently used thresholds for defining iron
deficiency (<12 and <15 ng mL−1) are based on international
guidelines informed by consensus meetings undertaken more
than 15 years ago (MMWR, 1998; World Health Organization,
2001), not on published evidence.
Strengths and limitations
This review describes the landscape of serum ferritin thresholds
used in the diagnosis of iron deficiency in pregnant women,
with a comprehensive summary of the existing thresholds
in use. Although we attempted to identify thresholds used
in unpublished and non-peer-reviewed sources by searching
the grey literature and discussing the preliminary results with
individuals with an interest in the subject, there is some risk of
missing data. The data collected in this review were derived from
a variety of study designs, and our investigation was centred on
the rationale for the threshold investigators chose in studies of
iron interventions in pregnancy. Investigating the use of other
markers of iron status was beyond the scope of this review.
There are many markers of iron status (such as transferrin
saturation [TSAT], soluble transferrin receptor [sTfR], hepcidin
among others) that can be used to estimate iron status in the con-
text of inflammation (Peyrin-Biroulet et al., 2015) when serum
ferritin levels are elevated but iron stores remain low. However,
the use of these markers in diagnosing iron deficiency in preg-
nancy is not widespread (Pavord et al., 2012). This is because the
impact of the physiological changes of pregnancy on measured
levels of these blood markers have not been widely agreed upon
(ACOG, 2008; Thomas et al., 2013).
The existing tools to assess the quality of studies (such as
the Jadad and Newcastle-Ottaway scales) were not appropriate
in assessing studies included in this review. As a result, we
developed a bespoke tool for assessing quality in primary studies
of thresholds, defining a target condition in the absence of an
existing gold standard. The strengths of our methods include
using first principles to develop a quality assessment tool, (Crespi
et al., 2014) a process used by other systematic reviewers to
develop similarly novel quality assessment tools (Tirlapur et al.,
2014). This tool was then reviewed and supported by external
experts with the experience of interventional and diagnostic
systematic reviews.
Interpretation
Variation in international thresholds defining anaemia has been
identified in the literature (New and Wirth, 2015). Discussions
on a more targeted approach to unifying definitions not just
for anaemia but iron deficiency and iron overload have ensued
(Garcia-Casal et al., 2014; Allard, 2015).
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There are several physiological changes occurring in preg-
nancy that may contribute to the variation in thresholds of serum
ferritin-defining iron deficiency in pregnancy. These include (i)
increased overall iron consumption compared to non-pregnant
states (Kaestel et al., 2015), (ii) second trimester plasma volume
expansion (i.e. haemodilution); (Costantine, 2014), (iii) phys-
iological rise in acute phase proteins secondary to pregnancy
(Kaestel et al., 2015), (iv) changes in inflammatory measures
in the final trimester of pregnancy (Viteri et al., 2012) and (v)
the uncertainty in the degree of increased iron consumption
and iron requirements in multiple pregnancies (Goodnight and
Newman, 2009).
There are other external factors influencing iron consumption
and therefore impacting the true threshold of serum ferritin
representing iron deficiency in pregnancy. These include the
effect of parasitic infections (such as malaria and hookworm
infection) (Mwangi et al., 2015) and inflammatory conditions,
including HIV (Clark et al., 2014), affecting the levels of serum
ferritin (an acute phase protein) measured independent of body
iron stores. The effect of these on measured serum ferritin levels
in pregnant and non-pregnant women is not clear, although steps
are being taken to understand these complexities (Suchdev et al.,
2016).
On reviewing the studies and national guidance referenced
in the studies included in this review, a paper published in the
British Journal of Haematology in 1998 was found to be the
most frequently cited study for choice of serum ferritin thresh-
old (van den Broek et al., 1998). In the study, van den Broek et al.
(1998) compared bone marrow aspirates samples of 93 Malaw-
ian pregnant women with serum ferritin levels from periph-
eral blood samples and found that a serum ferritin threshold
of <30 ng mL−1 had a sensitivity of 90% and a specificity of
85·1% in identifying individuals with absent iron stores on bone
marrow staining in pregnancy (van den Broek et al., 1998). In
this study, 44 of the 93 patients were HIV positive. The authors
attempted to correct for the impact of HIV infection by adjusting
the results based on C-reactive protein (CRP) levels. HIV infec-
tion is an independent contributor to iron deficiency (Minchella
et al., 2015). The effect of HIV status of included women in
the study by van den Broek et al. (1998) on the serum ferritin
estimates cannot be accurately estimated because of the small
sample size (private communication). Nevertheless, this study
continues to be used as a bench mark for defining iron defi-
ciency and is used as a method of justifying selecting a serum
ferritin threshold of <30 ng mL−1 defining iron deficiency in
numerous studies of iron interventions and national guidelines
(Sukrat and Sirichotiyakul, 2006; Ndyomugyenyi et al., 2008;
Shields et al., 2011; Pavord et al., 2012). After consulting national
guideline authors, senior obstetricians and haematologists in
the UK, we found that a threshold-defining iron deficiency of
<30 ng mL−1 in pregnancy is widely used in practice to guide
therapy.
There are multiple measures that can be taken to estab-
lish a unified, defining threshold for a target condition in the
absence of an established gold standard test threshold. A Health
Technology Assessment (HTA) report published in 2007 out-
lines the process of the test validation paradigm (Rutjes et al.,
2007). This involves using consensus methods to establish a
threshold from clinicians, scientists and policy makers followed
by continual assessment in new primary studies or existing data
sets on whether the threshold improves clinical outcomes for
patients and/or is cost effective (Rutjes et al., 2007).
Choosing a threshold based on consensus methods may be
challenging as a consensus between international experts on
this matter does not currently exist. The arguments for and
against using a more conservative threshold for defining iron
deficiency in pregnancy are multi-fold. A higher threshold (such
as <30 ng mL−1) may allow for issues surrounding the uncer-
tainty of iron consumption in pregnancy (singleton and multi-
ple), pregnancy-related pro-inflammatory changes and the effect
of physiological plasma volume expansion to be considered
(Costantine, 2014). However, a higher threshold can increase the
burden of the disease in countries where a very high prevalence
already exists (Garcia-Casal et al., 2014), also increasing the eco-
nomic burden for policy makers.
Good-quality primary studies exploring the optimal
serum ferritin threshold defining iron deficiency in preg-
nancy are required. The possibility of deriving a threshold
using pre-existing data from primary studies is an option
(Suchdev et al., 2016). Databases and individual patient data
meta-analyses may be helpful in providing extra information
to determine the optimum threshold defining iron deficiency.
However, care must be taken to ensure that thresholds derived
from novel primary studies or statistical analyses are rep-
resentative of the target condition and correlate to clinical
outcomes.
CONCLUSION
The current published literature, including national guidelines
and primary studies of iron interventions, showed variation in
defining the ferritin threshold of iron deficiency in pregnancy. A
unified definition of iron deficiency is required.
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